十二种肿瘤标志物联合检测对三种癌症诊断价值的探讨

Detecting 12 Multi-tumor Markers and Their Clinical Application Values in Three Kinds of Carcinomas

目的本文研究多肿瘤标志物(TM)联合定量检测对肝癌、胰腺癌和肺癌的临床应用价值。方法采用蛋白芯片检测系统(C-12),定量检测37例肝癌患者(A组)、25例胰腺癌患者(B组)、39例肺癌患者(C组)及70例良性相关疾病患者(D组)和62名正常人(对照组)血清中的12种肿瘤标志物,包括CA19-9、AFP、CEA、f-PSA、PSA、CA125、CA15-3、CA50、CA72-4、NSE、CF21-1、TSGF。结果(1)A组AFP、CA125、CEA、CA19-9、CA50和TSGF的检测结果较D组和对照组有极其显著想差异(P<0.01)。本组联合检测的灵敏度为89.5%,特异性为87.32%,阳性预测值为70.49%,阴性预测值为96.12%,准确度为87.89%;(2)B组CA19-9、CA125、CEA、CA72-4、CA15-3、CA50和TSGF的检测结果较D组和对照组有显著差异(P<0.01)。本组联合检测的灵敏度为82.7%,特异性为87.32%,阳性预测值为57.14%,阴性预测值为96.12%,准确度为86.55%;(3)C组CEA、CA15-3、CF21-1、NSE、CA72-4、CA50和TSGF的检测结果较D组和对照组有显著差异(P<0.01)。本组联合检测的灵敏度为80.9%,特异性为87.32%,阳性预测值为65.38%,阴性预测值为93.94%,准确度为85.87%。结论总之,多肿瘤标志物C-12联合检测提高相应肿瘤诊断的阳性率,不同类型的肿瘤选用相应多肿瘤标志物联合检测,这样可以为体检人群和癌症患者的早期筛查、术前和术后的临床跟踪等提供很好的依据。

Objectives To studay the clinical application value of quantitative detection of 12 tumor markers in hepatocellular carcinoma, pancreatic cancer and lung cancer. Methods the 12 tumor markers-CA125, CEA, CA19- 9, CA15-3, CA72-4, AFP, NSE, CA50, CF21-1, PSA, foPSA, and TSGF in the serum of 37 patients with hepatocellular carcinoma,25 patients with pancreatic cancer,39 patients with lung cancer,70 patients with benign disease and 62 healthy control persons were quantitatively detected by the protein bioehip determination system of C-12. Resuits The levels of AFP, CA125, CEA, CA19-9, CASO and TSGF in patients with hepatocellular carcinoma were significantly higher than those in patients with benign disease and controls. The sensitivity, specificity, positive and negative predivtive values, diagnostic efficiency by combinative detection were 89.58% , 87.32% , 70.49% , 96. 12% and87.89% , respectively. The levels of CEA, CA19-9, CA125, CA72-4, CA15-3, CA50 and TSGF in patients with pancreatic cancer were significabtly higher than those in patients with benign disease and controls （ P 〈0. 01 ）. The sensitivity, specificity, positive and negative predivtive values, diagnostic efficiency by combinative detection were 82. 76% ,87.32% ,57.14% ,96. 12% and 86. 55%, respectively. The levels of CEA, CA15-3, NSE, CF21-1, CA72-4, CAS0 and TSGF in patients with lung cancer were significabtly higher than those in patients with benign disease and controls（ P 〈 0. 01 ）. The sensitivity, specificity, positive and negative predivtive values, diagnostic efficiency by combinative detection were 80. 95% ,87.32% ,65.38% ,93.94% and 85.87% ,respectively. Conclusions In conclusion, combinative detection of various kinds of tumor markers should be adopted in diagnosis of different types of cancer. Detection of multi-tumor markers by using proteinchip can be applied clinically for early screening diagnosis of tumor, as well as the patient, s prognosis and therapeutic effect.